KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Invested Capital (2016 - 2025)

Historic Invested Capital for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $2.0 billion.

  • Halozyme Therapeutics' Invested Capital rose 295.45% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 295.45%. This contributed to the annual value of $1.9 billion for FY2024, which is 1810.19% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Invested Capital stood at $2.0 billion, which was up 295.45% from $1.8 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Invested Capital ranged from a high of $2.0 billion in Q3 2025 and a low of $852.3 million during Q1 2021
  • In the last 5 years, Halozyme Therapeutics' Invested Capital had a median value of $1.6 billion in 2023 and averaged $1.5 billion.
  • As far as peak fluctuations go, Halozyme Therapeutics' Invested Capital soared by 55159.06% in 2021, and later crashed by 553.98% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Invested Capital stood at $984.2 million in 2021, then skyrocketed by 70.28% to $1.7 billion in 2022, then fell by 5.54% to $1.6 billion in 2023, then increased by 18.1% to $1.9 billion in 2024, then rose by 7.76% to $2.0 billion in 2025.
  • Its Invested Capital was $2.0 billion in Q3 2025, compared to $1.8 billion in Q2 2025 and $2.0 billion in Q1 2025.